10X Genomics Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? 10X Genomics Inc trades at $57.3 (market cap $7.61B), while ZIM Integrated Shipping Services Ltd trades at $25.24 (market cap $2.96B). The key difference: 10X Genomics Inc is far larger — about 2.6× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | ZIM | |
|---|---|---|
Market Cap | $7.61B | $2.96B |
Sector | Health | Industrials |
52-Week High | $58.57 | $29.27 |
52-Week Low | $11.34 | $12.44 |
Enterprise Value | $7.14B | $6.81B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
ZIM Integrated Shipping Services trades at $24.91, down 1.19% for the day, with a bearish technical outlook and mixed fundamental picture. The stock shows attractive valuation metrics including P/S of 0.47 and P/B of 0.77, but faces profitability challenges with a 1.56% net margin. Recent Q1 2026 earnings missed expectations, while Q2 results are anticipated amid merger uncertainty with Hapag-Lloyd.
The outlook remains cautious with analyst consensus evenly split between Hold and Sell ratings and a $16.75 price target well below current levels. Key risks include regulatory hurdles for the proposed merger, declining revenue projections, and volatile shipping rates. The company's strong cash position provides some downside protection, but near-term headwinds outweigh growth catalysts.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →